Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis

Table 1 Patients with no known neurological disease

#	Diagnosis	Sex	Age at Death (yr)	PMI (hr)	Brain weight (g)	Braak stage	Thal phase	CERAD	LBD
1	normal	M	47	12	1383	I/II	0	0	no
2	normal	M	70	10.5	1388	I/II	1	0	no
3	normal	F	72	7	1406	I/II	0	0	no
4	normal	F	65	19	1207	0	1	0	no
5	normal	F	56	12	1416	I/II	n/a	0	no
6	normal	M	61	6	1369	0	1	0	no
7	normal	M	55	11.5	1448	0	n/a	0	no
8	normal	F	59	13	1166	0	n/a	0	no
9	normal	M	68	21	1330	I/II	0	0	no
10	normal	M	47	11	1333	I/II	n/a	A	no
11	normal	M	72	13.5	1320	I/II	3	A	no
12	normal	F	46	12	1228	0	n/a	0	no
13	normal	F	65	22	1206	I/II	1	0	no
14	normal	M	67	15	1545	I/II	2	A	no
15	normal	F	68	15	1151	I/II	0	0	no
16	normal	M	70	36	1755	0	0	0	no

Abbreviations: #: case number, Normal diagnosed neurologically normal, F female, M male, PMI postmortem interval, ALS stage stages 0–4 semiquantitatively assessed according to [14, 15]. Braak stage neurofibrillary tangle deposition according to [12, 13]. Thal phase amyloid deposition according to [108]. CERAD neuritic plaque deposition according to [76, 80]. LBD Lewy Body disease according to [75]. n/a data not available. no no LBD

ISSN: 2051-5960